Zijing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zijing Wang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Shijie Cai
Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford
11 shared publications - Adrian L. Harris
Department of Oncology, University of Oxford, Oxford, UK
10 shared publications - Aik Seng Ng
Nuffield Department of Clinical Laboratory Sciences, Radcliffe Department of Medicine University of Oxford Oxford UK
10 shared publications - Balázs Győrffy
Semmelweis University
10 shared publications - David J. Kerr
Nuffield Divisio Medical Labaratory Science, Radcliffe Department of Medicine John Radcliffe Hospital, Oxford OX3 9DU, UK
10 shared publications - Esther Bridges
MRC Translational Immune Discovery Unit, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford , Oxford
10 shared publications
Latest Publications
- 27 March 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (1) , 212-221
Colonoscopy-Related Adverse Events in the 21st Century: An Updated Systematic Review and Meta-Analysis
INTRODUCTION: Colonoscopy is one of the most commonly performed endoscopic procedures and is generally considered low-risk. However, when adverse events (AEs) occur, they can present significant challenges in clinical practice. The aim of this study was to estimate the global incidence of colonoscopy-related AEs. METHODS: We searched multiple databases for population-based studies reporting the incidence of colonoscopy-related AEs up to December 22, 2024. Meta-analyses were conducted for both gastrointestinal and nongastrointestinal AEs. Subgroup analyses were performed based on factors including World Health Organization region, publication year, sample size, data collection method, and study design. RESULTS: Among the 30,818 records identified, 82 population-based studies from 24 countries were included, involving a total of 38.5 million colonoscopies. The estimated incidence per 10,000 colonoscopies was as follows: gastrointestinal AEs, including perforation (5.15; 95% confidence interval [CI] 4.19–6.34, I 2 = 99%), bleeding (18.39; 95% CI 13.53–24.99, I 2 = 100%), and splenic injury (0.61; 95% CI 0.43–0.85, I 2 = 93%); nongastrointestinal AEs, including cardiovascular events (52.11; 95% CI 18.67–144.59, I 2 = 100%), respiratory events (4.26; 95% CI 0.73–24.99, I 2 = 100%), and deaths related to colonoscopy (0.18; 95% CI 0.10–0.34, I 2 = 74%). Subgroup analyses yielded partially divergent findings. The majority of the included studies exhibited a low to moderate risk of bias. DISCUSSION: This comprehensive meta-analysis provides valuable insights into the global incidence of colonoscopy-related AEs and underscores the imperative need for continuous efforts to enhance the safety of this procedure.
- 27 March 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (1) , 212-221
Colonoscopy-Related Adverse Events in the 21st Century: An Updated Systematic Review and Meta-Analysis
INTRODUCTION: Colonoscopy is one of the most commonly performed endoscopic procedures and is generally considered low-risk. However, when adverse events (AEs) occur, they can present significant challenges in clinical practice. The aim of this study was to estimate the global incidence of colonoscopy-related AEs. METHODS: We searched multiple databases for population-based studies reporting the incidence of colonoscopy-related AEs up to December 22, 2024. Meta-analyses were conducted for both gastrointestinal and nongastrointestinal AEs. Subgroup analyses were performed based on factors including World Health Organization region, publication year, sample size, data collection method, and study design. RESULTS: Among the 30,818 records identified, 82 population-based studies from 24 countries were included, involving a total of 38.5 million colonoscopies. The estimated incidence per 10,000 colonoscopies was as follows: gastrointestinal AEs, including perforation (5.15; 95% confidence interval [CI] 4.19–6.34, I 2 = 99%), bleeding (18.39; 95% CI 13.53–24.99, I 2 = 100%), and splenic injury (0.61; 95% CI 0.43–0.85, I 2 = 93%); nongastrointestinal AEs, including cardiovascular events (52.11; 95% CI 18.67–144.59, I 2 = 100%), respiratory events (4.26; 95% CI 0.73–24.99, I 2 = 100%), and deaths related to colonoscopy (0.18; 95% CI 0.10–0.34, I 2 = 74%). Subgroup analyses yielded partially divergent findings. The majority of the included studies exhibited a low to moderate risk of bias. DISCUSSION: This comprehensive meta-analysis provides valuable insights into the global incidence of colonoscopy-related AEs and underscores the imperative need for continuous efforts to enhance the safety of this procedure.
- Open Access
- 19 December 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Bestrophin-4 relays HES4 and interacts with TWIST1 to suppress epithelial-to-mesenchymal transition in colorectal cancer cells
Bestrophin isoform 4 (BEST4) is a newly identified subtype of the calcium-activated chloride channel family. Analysis of colonic epithelial cell diversity by single-cell RNA-sequencing has revealed the existence of a cluster of BEST4+ mature colonocytes in humans. However, if the role of BEST4 is involved in regulating tumour progression remains largely unknown. In this study, we demonstrate that BEST4 overexpression attenuates cell proliferation, colony formation, and mobility in colorectal cancer (CRC) in vitro, and impedes the tumour growth and the liver metastasis in vivo. BEST4 is co-expressed with hairy/enhancer of split 4 (HES4) in the nucleus of cells, and HES4 signals BEST4 by interacting with the upstream region of the BEST4 promoter. BEST4 is epistatic to HES4 and downregulates TWIST1, thereby inhibiting epithelial-to-mesenchymal transition (EMT) in CRC. Conversely, knockout of BEST4 using CRISPR/Cas9 in CRC cells revitalises tumour growth and induces EMT. Furthermore, the low level of the BEST4 mRNA is correlated with advanced and the worse prognosis, suggesting its potential role involving CRC progression.
- 19 December 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessBestrophin-4 relays HES4 and interacts with TWIST1 to suppress epithelial-to-mesenchymal transition in colorectal cancer cells
Bestrophin isoform 4 (BEST4) is a newly identified subtype of the calcium-activated chloride channel family. Analysis of colonic epithelial cell diversity by single-cell RNA-sequencing has revealed the existence of a cluster of BEST4+ mature colonocytes in humans. However, if the role of BEST4 is involved in regulating tumour progression remains largely unknown. In this study, we demonstrate that BEST4 overexpression attenuates cell proliferation, colony formation, and mobility in colorectal cancer (CRC) in vitro, and impedes the tumour growth and the liver metastasis in vivo. BEST4 is co-expressed with hairy/enhancer of split 4 (HES4) in the nucleus of cells, and HES4 signals BEST4 by interacting with the upstream region of the BEST4 promoter. BEST4 is epistatic to HES4 and downregulates TWIST1, thereby inhibiting epithelial-to-mesenchymal transition (EMT) in CRC. Conversely, knockout of BEST4 using CRISPR/Cas9 in CRC cells revitalises tumour growth and induces EMT. Furthermore, the low level of the BEST4 mRNA is correlated with advanced and the worse prognosis, suggesting its potential role involving CRC progression.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
GTP cyclohydrolase (GCH1) is the rate-limiting enzyme for tetrahydrobiopterin (BH4) biosynthesis. The catalysis of BH4 biosynthesis is tightly regulated for physiological neurotransmission, inflammation, and vascular tone. Paradoxically, BH4 has emerged as an oncometabolite regulating tumor growth, but the effects on tumor development remain controversial. Here we found that GCH1 potentiates the growth of triple-negative breast cancer (TNBC) and HER2+ breast cancer and transforms non-tumor breast epithelial cells. Independent of BH4 production, GCH1 protein induced epithelial-to-mesenchymal transition IEMT) by binding to Vim, which was mediated by HSP90. Conversely, GCH1 ablation impaired tumor growth, suppressed Vim in TNBC, and inhibited EGFR/ERK signaling while activating the p53 pathway in estrogen receptor-positive tumor cells. GCH1 deficiency increases tumor cell sensitivity to HSP90 inhibition and endocrine treatments. Additionally, high GCH1 corelated with poor breast cancer survival. Together, this study reveals an enzyme-independent oncogenic role of GCH1, presenting it as a potential target for therapeutic development.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
GTP cyclohydrolase (GCH1) is the rate-limiting enzyme for tetrahydrobiopterin (BH4) biosynthesis. The catalysis of BH4 biosynthesis is tightly regulated for physiological neurotransmission, inflammation, and vascular tone. Paradoxically, BH4 has emerged as an oncometabolite regulating tumor growth, but the effects on tumor development remain controversial. Here we found that GCH1 potentiates the growth of triple-negative breast cancer (TNBC) and HER2+ breast cancer and transforms non-tumor breast epithelial cells. Independent of BH4 production, GCH1 protein induced epithelial-to-mesenchymal transition IEMT) by binding to Vim, which was mediated by HSP90. Conversely, GCH1 ablation impaired tumor growth, suppressed Vim in TNBC, and inhibited EGFR/ERK signaling while activating the p53 pathway in estrogen receptor-positive tumor cells. GCH1 deficiency increases tumor cell sensitivity to HSP90 inhibition and endocrine treatments. Additionally, high GCH1 corelated with poor breast cancer survival. Together, this study reveals an enzyme-independent oncogenic role of GCH1, presenting it as a potential target for therapeutic development.
- Open Access
- 13 October 2023
- Published by American Association for Cancer Research (AACR)
Data from GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent Manner
GTP cyclohydrolase (GCH1) is the rate-limiting enzyme for tetrahydrobiopterin (BH4) biosynthesis. The catalysis of BH4 biosynthesis is tightly regulated for physiological neurotransmission, inflammation, and vascular tone. Paradoxically, BH4 has emerged as an oncometabolite regulating tumor growth, but the effects on tumor development remain controversial. Here, we found that GCH1 potentiated the growth of triple-negative breast cancer (TNBC) and HER2+ breast cancer and transformed nontumor breast epithelial cells. Independent of BH4 production, GCH1 protein induced epithelial-to-mesenchymal transition by binding to vimentin (Vim), which was mediated by HSP90. Conversely, GCH1 ablation impaired tumor growth, suppressed Vim in TNBC, and inhibited EGFR/ERK signaling while activating the p53 pathway in estrogen receptor–positive tumor cells. GCH1 deficiency increases tumor cell sensitivity to HSP90 inhibition and endocrine treatments. In addition, high GCH1 correlated with poor breast cancer survival. Together, this study reveals an enzyme-independent oncogenic role of GCH1, presenting it as a potential target for therapeutic development.Significance:GTP cyclohydrolase functions as an oncogene in breast cancer and binds vimentin to induce epithelial-to-mesenchymal transition independently of its enzyme activity, which confers targetable vulnerabilities for developing breast cancer treatment strategies.
- 13 October 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent Manner
GTP cyclohydrolase (GCH1) is the rate-limiting enzyme for tetrahydrobiopterin (BH4) biosynthesis. The catalysis of BH4 biosynthesis is tightly regulated for physiological neurotransmission, inflammation, and vascular tone. Paradoxically, BH4 has emerged as an oncometabolite regulating tumor growth, but the effects on tumor development remain controversial. Here, we found that GCH1 potentiated the growth of triple-negative breast cancer (TNBC) and HER2+ breast cancer and transformed nontumor breast epithelial cells. Independent of BH4 production, GCH1 protein induced epithelial-to-mesenchymal transition by binding to vimentin (Vim), which was mediated by HSP90. Conversely, GCH1 ablation impaired tumor growth, suppressed Vim in TNBC, and inhibited EGFR/ERK signaling while activating the p53 pathway in estrogen receptor–positive tumor cells. GCH1 deficiency increases tumor cell sensitivity to HSP90 inhibition and endocrine treatments. In addition, high GCH1 correlated with poor breast cancer survival. Together, this study reveals an enzyme-independent oncogenic role of GCH1, presenting it as a potential target for therapeutic development.Significance:GTP cyclohydrolase functions as an oncogene in breast cancer and binds vimentin to induce epithelial-to-mesenchymal transition independently of its enzyme activity, which confers targetable vulnerabilities for developing breast cancer treatment strategies.